The Role of Machine Learning and Artificial Intelligence in Drug Discovery and Clinical Care of Pulmonary
Evelyne Bischof1, Chaim Haber2, Niklas Lidströmer3
1Department of Clinical Medicine, Shanghai University of Medicine and Health Sciences; Department of Longevity Medicine at Sheba Longevity Center, Sheba Medical Center, Tel Hashomer, Israel; Grey School of Medicine, Tel Aviv University.
Abstract:
Pulmonary hypertension (PH) is a severe and oftentimes fatal disease with a high degree of clinical variability. Its complexity necessitates a multifaceted approach, with clinical and prognostic results significantly improved with earlier identification and initiation of treatment. Developments in artificial intelligence (AI) and machine learning (ML) allow earlier diagnosis, individualized treatments, and new therapeutic options, which have already shown real potential to improve patient outcomes; such an intricate approach was not feasible before the AI innovations of the last decade. This article outlines the current applications of AI and ML for diagnostics, treatment optimization, surveillance, and drug discovery for PH.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
